Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Nasal Polyposis Treatment Market Snapshot (2023 to 2033)

Expected to be valued at US$ 4.6 billion by the end of 2023, the market for nasal polyposis treatment is likely to expand at a CAGR of 6.7% until 2033. By the conclusion of the 2023-2033 forecast period, a valuation of US$ 8.8 billion is anticipate for nasal polyposis treatment.

Growing prevalence of chronic rhinosinusitis with nasal polyps especially in elderly population is one of the major factors propelling industry growth. Surging inflammatory diseases around the world is also expected to contribute to growth of nasal polyposis market.

Advancements in technology for removal of nasal polyps and increase in research and development is expected to lead to novel therapeutic treatment for nasal polyps which will lead to market expansion.

Report Attribute Details
Expected Market Value (2023) US$ 4.6 billion
Anticipated Forecast Value (2033) US$ 8.8 billion
Projected Growth Rate (2023 to 2033) CAGR 6.7%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Nasal Polyposis treatment management Demand Analysis vs. Forecast 2023 to 2033

The market for Nasal Polyposis treatment was worth US$ 3.7 billion in 2018, while growing at a CAGR of 4.45% during the historical period. With each passing decade, extensive research & development activities are being conducted by healthcare professionals. These have translated into extensive clinical trials for potential drug candidates, or the introduction of novel therapies and diagnostics, which is expected to provide impetus to the market. For example, Hoffmann-La Roche completed its Phase III study on March 11, 2019, which was conducted to test effectiveness and safety of omalizumab in comparison with placebo in patients having chronic rhinosinusitis with nasal polyps who have witnessed insufficient response to standard treatments.

On the other hand, advancements in technology, such as nasal endoscopy and computerized tomography, better-quality healthcare facilities with innovative drug development for treatment of nasal polyps, and initiatives by governments in spreading awareness about nasal polyps, is expected to witness lucrative growth in market of Nasal polyposis during the projected period.

The growth in the number of rhinitis therapeutics distributed through the retail pharmacies and increasing number of these pharmacies in developed countries is anticipated to create opportunities and space for market expansion. In addition, patients generally opt for retail pharmacies for purchasing drugs, as these are easily accessible. Thus, presenting opportunities for future growth of nasal polyposis market.

After a comprehensive analysis of above-mentioned factors, the market for nasal polyposis is projected to attain a valuation of USD 8.8 billion by end of the forecast period, while exhibiting a CAGR of 6.7%.

Which are Some Prominent Drivers of the Nasal Polyposis treatment market?

The adoption of pipeline therapies in Nasal polyposis market like Fasenra (benralizumab), Tezepelumab, CBP-201, and others are expected to fuel growth of the market in the forecast period. With the launch of Fasenra (benralizumab) in 2022 and expected launch of Tezepelumab this year, the market is anticipated to witness growth during the forecast period. Both Fasenra and Tezepelumab is estimated to garner nearly USD 5 million in the first year of its launch which will aid in the expansion of targeted industry.

The recommendation from regulatory bodies for approval of authorised new drugs used in nasal polyposis treatment, is also anticipated to propel growth of this market, during the forecast period. For example, in June, 2020, Novartis got a positive recommendation on Xolair, its approved product. It is used for the treatment of adults who are suffering from serious chronic rhinosinusitis with nasal polyps. Likewise, Xolair is used for treating nasal polyps targeting and blocking immunoglobulin E (IgE), that aids in decreasing the size of nasal polyps. This will support market expansion.

With ab expected increase in the launch of biologics in the upcoming years, the ratio of patients opting for surgery might decline because of the excellent effectiveness of biologics and also fewer possibility of recurrence of the disease, augmenting the industry’s growth. Furthermore, the surge in market size of Nasal Polyposis is a direct result of the anticipated approval of emerging therapies and the rising Nasal Polyposis patient population.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Projected to be Faced by the Market?

Dearth of Skilled Professionals and High Cost of Treatment will restrain market growth

Dearth of skilled and qualified healthcare professionals who are not able to treat these patients with appropriate treatments could hold back growth of the global nasal polyposis drugs market during the projected period. The massive expenditure associated with nasal polyposis treatment is also expected to hinder market expansion.

On the other hand, factors such as bleeding, visual disturbances, inflammation, and cerebrospinal fluid leak linked with surgical removal of nasal polyposis and several adverse reactions because of steroid therapy, may restrain market growth.

Region-Wise Insights

How will Nasal Polyposis Treatment progress across North America?

Rising Incidence of Chronic Rhinosinusitis to encourage Patients to Opt for Treatment

North America is anticipated to dominate the nasal polyposis treatment market, capturing a 41.5% market share. This region is projected to reflect a CAGR of 6.1% from 2023 to 2033. The growth is attributable to increasing incidence of several cancers and allergic disorders like asthma, sinusitis, and others. Moreover, research activities in the United States coupled with surging approvals from regulatory bodies are anticipated to fuel growth of this market during the projected period.

The presence of a huge target population, affected by chronic rhinosinusitis with nasal polyposis and rising sinus surgeries conducted in the United States are the major factors attributed to hold dominance in this region. Additionally, the approvals by the Federal Agency for the reimbursement of money used for treatment of nasal polyps will aid in regional market expansion.

For example, in June 2020, Intersect ENT, a medical device company, was approved by Centers for Medicare and Medicaid Services to SINUVA Sinus Implant for reimbursement, with a New C–Code. Likewise, New C Code for SINUVA will simplify the reimbursement process for ENT physicians and their practices which will boost regional market expansion. It will provide Medicare patients easier access to this novel drug eluting sinus implant. This will support in regional expansion of the market.

What is the Growth Outlook for Nasal Polyposis Treatment in the Asia Pacific?

Healthcare Providers finding Ground amid Increased Cases of Respiratory Disorders

According to Future Market Insights, Asia Pacific is expected to register a CAGR of 7% during the forecast period ranging from 2023 to 2033, with respect to treatment for nasal polyposis. The growth is expected to be driven by prevalence of allergic disorders and stable growth of the pharmaceutical industry in recent years. Moreover, China plays a crucial role in the Asia pacific region owing to its high population and high degree of government initiatives in the healthcare sector. Also, Ongoing trials in this region are expected to further stimulate market growth.

The presence of a large patient pool suffering from inflammatory and respiratory disorders in developing countries such as China and India, and growth in sinus surgeries conducted in developed countries in the region, are expected to fuel the nasal polyposis treatment market.

Similarly, increasing number of patients affected by nasal polyposis, government initiatives to promote awareness, and increasing demand for treatment are some of the other factors responsible for market expansion in this region. Presence of huge population is also one of the factors anticipated to positively influence nasal polyposis industry growth.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category wise Insights

Based on Type of Treatment, which approach are Patients likely to Opt for?

Demand for Corticosteroids to Surge Prolifically in the Coming Decade

By type of treatment, corticosteroids are projected to account for 55% of all approaches. It is projected to witness CAGR of 9% during the forecast period. The growth is attributed to rising demand for corticosteroids treatment and its availability in numerous dosage forms such as injections, intranasal sprays, and drops according to suitability of the patient.

Furthermore, the availability of various corticosteroids as topical formulations and aerosols which have the ability to reduce the size of nasal polyposis, and therefore heal the nasal polyps in suffered patients is expected to contributed in significant share of market revenue. Likewise, Nasonex (mometasone) and Xhance (fluticasone propionate) are two major corticosteroid brands available in the market that will boost market growth. Also, patient compliance for creams is more compared to other dosage forms. This will aid in growth of the segment during the forecast period.

Which End User will likely comprise the Bulk of all Nasal Polyposis Treatment?

Hospitals to be the Primary Point of Contact for seeking Nasal Polyposis Treatment

Hospitals are anticipated to lead the market when it comes to seeking treatment for nasal polyps, with an expected market share of 64.2%. The growth of this segment is attributed to surging demand for sinus surgeries for the removal of nasal polyposis, leading to increased hospitalization and extensive range of services provided by hospitals at a single site.

Start-ups in the Nasal Polyposis Treatment Market

Start-ups help in understanding the outlook of any market. Start-ups also have the potential to generate higher returns which directly benefits in expansion of any market. This is because these are typically more efficient at converting inputs into outputs. These are more flexible and adaptable, able to shift quickly in response to changing market conditions. Some of the start-ups that will aid in expansion of Nasal Polyposis treatment market are:

  • Laurimed is a redwood, United states-based start-up that has developed physician-based devices to remove nasal polyps without the requirement for invasive surgery. The device PolypVac is an FDA 510(k) cleared (K163247) micro debrider, specifically designed to eliminate nasal polyps in the ENT office; Its products are available in two sizes - 3.3 mm and 4.0 mm. The tip of the device is designed to be flexible with multi-angle, malleable and 360? rotatable shaft. This company also offers Cliq Pump, which provides suction airflow. This company was founded in 2005.
  • Founded in 2003, Intersect ENT is a Menlo Park, United states-based start-up. This company is developer of a drug-releasing implant for the treatment of sinusitis. The company has developed drug-releasing implants called CE marked and FDA-approved dissolvable implants for the treatment of chronic sinusitis knowns as Propel, Propel Mini and PROPEL Contour. The company has claimed that the device is clinically proved to prevent obstruction of the ethmoid sinus following surgery. This firm has obtained total funding of US$ 76.5 million over four rounds. The latest funding round was held on May11, 2020 in which it was granted US$ 65 million. The main investors in this start-up are Norwest Venture Partners, USA Venture Partners, Kleiner Perkins, PTV Healthcare Capital, Deerfield and 4 others.

Market Competition

The nasal polyposis treatment market is competitive and consists of several major players. Major players are creating novel delivery systems for the treatment of nasal polyps. This is expected to propel nasal polyposis treatment market. The major players in the market are: Sanofi, Merck & Co, Inc., OptiNose US, Inc., Intersect ENT, Inc., Pfizer, Regeneron Pharmaceuticals, Inc., Novartis AG, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Inc.

Some recent developments in the market are:

Key market players are concentrating on adoption of inorganic growth strategies such as acquisition, partnerships, and collaboration in order to improve its product portfolio. This is anticipated to drive the global Nasal Polyposis treatment market.

  • In July 2021, GSK plc. declared that Nucala (Mepolizumab) is approved by United states FDA for chronic bilateral nasal polyposis related with chronic rhinosinusitis. Also, the company’s investigational site at Boise, Idaho, is working on a study to determine effectiveness and safety of Depemokimab (GSK3511294) in patients suffering from chronic rhinosinusitis with nasal polyposis. It is presently doing phase 3 trial and will complete this study by January 2025.
  • In 2020, the United States Food and Drug Administration approved authorized use of Dupixent for adults with nasal polyps accompanied by chronic rhinosinusitis. It is the first treatment approved for uncontrolled chronic rhinosinusitis with nasal polyps and also reduces dependence on nasal polyp surgery and oral steroids.
  • In 2020, Roche Holding AG, a pharmaceutical company, had successfully completed and declared the positive result from two Phase III multicenter studies evaluating Xolair for the treatment of adults with chronic rhinosinusitis with nasal polyposis.??

Report Scope

Report Attribute Details
Market Value in 2023 US$ 4.6 billion
Market Value in 2033 US$ 8.8 billion
Growth Rate CAGR of 6.7 % from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US$ Billion and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
  • Type of Treatment
  • End User
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa
Key Countries Profiled
  • United States
  • Canada
  • Brazil
  • Mexico
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • India
  • China
  • Japan
  • South Korea
  • Indonesia
  • Singapore
  • Thailand
  • Australia
  • New Zealand
  • GCC Countries
  • South Africa
  • Israel
Key Companies Profiled
  • Sanofi S.A
  • Merck & Co. Inc.
  • OptiNose USA Inc.
  • Intersect ENT Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • GSK plc.
  • F. Hoffmann- La Roche Ltd.
  • Teva Pharmaceutical Industries Inc.
  • Novartis AG
Customization Available Upon Request

Key Segments Profiled in the Nasal Polyposis Treatment Industry Survey

By Type of Treatment:

  • Pharmacological Therapies
    • Corticosteroids
    • Antibiotics
    • Leukotriene Inhibitors
    • Others
  • Surgeries
    • Polypectomy
    • Functional Endoscopic Sinus Surgery

By End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Frequently Asked Questions

What is the Projected CAGR of the Nasal Polyposis Treatment Market by 2033?

The projected CAGR of the nasal polyposis treatment market by 2033 is 6.7%.

What is the Projected Nasal Polyposis Treatment Market value for 2033?

The projected market value for 2033 is US$ 8.8 billion.

What is the Current Market Valuation of the Nasal Polyposis Treatment Market?

The market is estimated to secure a valuation of US$ 4.6 billion in 2023.

Which Industry is the Key Consumer of the Nasal Polyposis Treatment Market?

The key consumer of the nasal polyposis treatment market is the healthcare industry.

Why is the North America Market Growing Remarkably Fast in the Nasal Polyposis Treatment Market?

The North America market is growing remarkably fast due to the increasing prevalence of nasal polyposis.

Table of Content

1. Executive Summary | Nasal Polyposis Treatment Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type of Treatment

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Type of Treatment, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type of Treatment, 2023 to 2033

        5.3.1. Pharmacological Therapies

            5.3.1.1. Corticosteroids

            5.3.1.2. Antibiotics

            5.3.1.3. Leukotriene Inhibitors

            5.3.1.4. Others

        5.3.2. Surgeries

            5.3.2.1. Polypectomy

            5.3.2.2. Functional Endoscopic Sinus Surgery

    5.4. Y-o-Y Growth Trend Analysis By Type of Treatment, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Type of Treatment, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033

        6.3.1. Hospitals

        6.3.2. Ambulatory Surgical Centres

        6.3.3. Specialty Clinics

    6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Europe

        7.3.4. Asia Pacific

        7.3.5. Middle East and Africa

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        8.2.1. By Country

            8.2.1.1. United States

            8.2.1.2. Canada

        8.2.2. By Type of Treatment

        8.2.3. By End User

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Type of Treatment

        8.3.3. By End User

    8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Type of Treatment

        9.2.3. By End User

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Type of Treatment

        9.3.3. By End User

    9.4. Key Takeaways

10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. United Kingdom

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Europe

        10.2.2. By Type of Treatment

        10.2.3. By End User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Type of Treatment

        10.3.3. By End User

    10.4. Key Takeaways

11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. China

            11.2.1.2. Japan

            11.2.1.3. South Korea

            11.2.1.4. Singapore

            11.2.1.5. Thailand

            11.2.1.6. Indonesia

            11.2.1.7. Australia

            11.2.1.8. New Zealand

            11.2.1.9. Rest of Asia Pacific

        11.2.2. By Type of Treatment

        11.2.3. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Type of Treatment

        11.3.3. By End User

    11.4. Key Takeaways

12. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. GCC Countries

            12.2.1.2. South Africa

            12.2.1.3. Israel

            12.2.1.4. Rest of Middle East and Africa

        12.2.2. By Type of Treatment

        12.2.3. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Type of Treatment

        12.3.3. By End User

    12.4. Key Takeaways

13. Key Countries Market Analysis

    13.1. United States

        13.1.1. Pricing Analysis

        13.1.2. Market Share Analysis, 2022

            13.1.2.1. By Type of Treatment

            13.1.2.2. By End User

    13.2. Canada

        13.2.1. Pricing Analysis

        13.2.2. Market Share Analysis, 2022

            13.2.2.1. By Type of Treatment

            13.2.2.2. By End User

    13.3. Brazil

        13.3.1. Pricing Analysis

        13.3.2. Market Share Analysis, 2022

            13.3.2.1. By Type of Treatment

            13.3.2.2. By End User

    13.4. Mexico

        13.4.1. Pricing Analysis

        13.4.2. Market Share Analysis, 2022

            13.4.2.1. By Type of Treatment

            13.4.2.2. By End User

    13.5. Germany

        13.5.1. Pricing Analysis

        13.5.2. Market Share Analysis, 2022

            13.5.2.1. By Type of Treatment

            13.5.2.2. By End User

    13.6. United Kingdom

        13.6.1. Pricing Analysis

        13.6.2. Market Share Analysis, 2022

            13.6.2.1. By Type of Treatment

            13.6.2.2. By End User

    13.7. France

        13.7.1. Pricing Analysis

        13.7.2. Market Share Analysis, 2022

            13.7.2.1. By Type of Treatment

            13.7.2.2. By End User

    13.8. Spain

        13.8.1. Pricing Analysis

        13.8.2. Market Share Analysis, 2022

            13.8.2.1. By Type of Treatment

            13.8.2.2. By End User

    13.9. Italy

        13.9.1. Pricing Analysis

        13.9.2. Market Share Analysis, 2022

            13.9.2.1. By Type of Treatment

            13.9.2.2. By End User

    13.10. China

        13.10.1. Pricing Analysis

        13.10.2. Market Share Analysis, 2022

            13.10.2.1. By Type of Treatment

            13.10.2.2. By End User

    13.11. Japan

        13.11.1. Pricing Analysis

        13.11.2. Market Share Analysis, 2022

            13.11.2.1. By Type of Treatment

            13.11.2.2. By End User

    13.12. South Korea

        13.12.1. Pricing Analysis

        13.12.2. Market Share Analysis, 2022

            13.12.2.1. By Type of Treatment

            13.12.2.2. By End User

    13.13. Singapore

        13.13.1. Pricing Analysis

        13.13.2. Market Share Analysis, 2022

            13.13.2.1. By Type of Treatment

            13.13.2.2. By End User

    13.14. Thailand

        13.14.1. Pricing Analysis

        13.14.2. Market Share Analysis, 2022

            13.14.2.1. By Type of Treatment

            13.14.2.2. By End User

    13.15. Indonesia

        13.15.1. Pricing Analysis

        13.15.2. Market Share Analysis, 2022

            13.15.2.1. By Type of Treatment

            13.15.2.2. By End User

    13.16. Australia

        13.16.1. Pricing Analysis

        13.16.2. Market Share Analysis, 2022

            13.16.2.1. By Type of Treatment

            13.16.2.2. By End User

    13.17. New Zealand

        13.17.1. Pricing Analysis

        13.17.2. Market Share Analysis, 2022

            13.17.2.1. By Type of Treatment

            13.17.2.2. By End User

    13.18. GCC Countries

        13.18.1. Pricing Analysis

        13.18.2. Market Share Analysis, 2022

            13.18.2.1. By Type of Treatment

            13.18.2.2. By End User

    13.19. South Africa

        13.19.1. Pricing Analysis

        13.19.2. Market Share Analysis, 2022

            13.19.2.1. By Type of Treatment

            13.19.2.2. By End User

    13.20. Israel

        13.20.1. Pricing Analysis

        13.20.2. Market Share Analysis, 2022

            13.20.2.1. By Type of Treatment

            13.20.2.2. By End User

14. Market Structure Analysis

    14.1. Competition Dashboard

    14.2. Competition Benchmarking

    14.3. Market Share Analysis of Top Players

        14.3.1. By Regional

        14.3.2. By Type of Treatment

        14.3.3. By End User

15. Competition Analysis

    15.1. Competition Deep Dive

        15.1.1. Sanofi S.A

            15.1.1.1. Overview

            15.1.1.2. Product Portfolio

            15.1.1.3. Profitability by Market Segments

            15.1.1.4. Sales Footprint

            15.1.1.5. Strategy Overview

                15.1.1.5.1. Marketing Strategy

        15.1.2. Merck & Co, Inc.

            15.1.2.1. Overview

            15.1.2.2. Product Portfolio

            15.1.2.3. Profitability by Market Segments

            15.1.2.4. Sales Footprint

            15.1.2.5. Strategy Overview

                15.1.2.5.1. Marketing Strategy

        15.1.3. OptiNose US, Inc.

            15.1.3.1. Overview

            15.1.3.2. Product Portfolio

            15.1.3.3. Profitability by Market Segments

            15.1.3.4. Sales Footprint

            15.1.3.5. Strategy Overview

                15.1.3.5.1. Marketing Strategy

        15.1.4. Intersect ENT, Inc.

            15.1.4.1. Overview

            15.1.4.2. Product Portfolio

            15.1.4.3. Profitability by Market Segments

            15.1.4.4. Sales Footprint

            15.1.4.5. Strategy Overview

                15.1.4.5.1. Marketing Strategy

        15.1.5. Pfizer Inc

            15.1.5.1. Overview

            15.1.5.2. Product Portfolio

            15.1.5.3. Profitability by Market Segments

            15.1.5.4. Sales Footprint

            15.1.5.5. Strategy Overview

                15.1.5.5.1. Marketing Strategy

        15.1.6. Regeneron Pharmaceuticals, Inc.

            15.1.6.1. Overview

            15.1.6.2. Product Portfolio

            15.1.6.3. Profitability by Market Segments

            15.1.6.4. Sales Footprint

            15.1.6.5. Strategy Overview

                15.1.6.5.1. Marketing Strategy

        15.1.7. Novartis AG

            15.1.7.1. Overview

            15.1.7.2. Product Portfolio

            15.1.7.3. Profitability by Market Segments

            15.1.7.4. Sales Footprint

            15.1.7.5. Strategy Overview

                15.1.7.5.1. Marketing Strategy

        15.1.8. GlaxoSmithKline plc

            15.1.8.1. Overview

            15.1.8.2. Product Portfolio

            15.1.8.3. Profitability by Market Segments

            15.1.8.4. Sales Footprint

            15.1.8.5. Strategy Overview

                15.1.8.5.1. Marketing Strategy

        15.1.9. F. Hoffmann-La Roche Ltd

            15.1.9.1. Overview

            15.1.9.2. Product Portfolio

            15.1.9.3. Profitability by Market Segments

            15.1.9.4. Sales Footprint

            15.1.9.5. Strategy Overview

                15.1.9.5.1. Marketing Strategy

        15.1.10. Teva Pharmaceutical Industries Inc

            15.1.10.1. Overview

            15.1.10.2. Product Portfolio

            15.1.10.3. Profitability by Market Segments

            15.1.10.4. Sales Footprint

            15.1.10.5. Strategy Overview

                15.1.10.5.1. Marketing Strategy

16. Assumptions & Acronyms Used

17. Research Methodology

Recommendations

Healthcare

Respiratory Device Market

Published : April 2024

Healthcare

Mucosal Atomization Device Market

Published : February 2024

Explore Healthcare Insights

View Reports

Nasal Polyposis Treatment Market